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INTRODUCTION
Malignant gliomas are the most common primary cerebral
neoplasm in adults. Unfortunately, their clinical courses are
very rapid, and they commonly have miserable prognosis.
There are several presumed reasons for the poor prognosis
associated with high-grade glioma (HGG)14). First, the tumor
cells in HGG extensively infiltrate the surrounding brain
parenchyma, thereby limiting the overall utility of surgical
resection. Second, the blood-brain barrier is an obstacle to
the adequate delivery of chemotherapy agents to brain
tumors. Third, HGG is refractory to most cancer cytotoxic
agents, and the occasional responses are often short lived,
with the rapid development of resistance, a direct conse-
quence of genetic transformation and the tumor hetero-
geneity characteristic of this neoplasm. The expression of
methylguanine methyltransferase (MGMT) is thought to
be the major mechanism of this resistance. Therefore,
surgical resection alone has limitations in the treatment of
HGG. The standard therapy for malignant glioma consists
of surgical removal to the extent that is safely feasible,
followed by radiotherapy (RTx) with or without adjuvant
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chemotherapy (CTx)16,17). Regardless of this multimodality
treatment, the prognosis for patients with malignant glioma
remains unsatisfactory. The median survival for patients
with glioblastoma is typically in the range of 9-12 months,
with two-year survival rates of only 8%-12% and long-
term survival rates of less than 5%6,8). Considering the
awful prognosis for malignant glioma, continuous research
and the development of new treatment modalities and
chemotherapeutic agents are urgently needed.
Stupp et al.13,15) reported that the concomitant admini-
stration of temozolomide (TMZ) with fractionated RTx,
followed by up to six cycles of adjuvant TMZ, for newly
diagnosed glioblastoma resulted in a clinically meaningful
and statistically significant survival benefit, with minimal
additional toxicity. Most recently, the effectiveness of this
concomitant chemoradiotherapy (CCRT) has been reported
in many studies2,11,12,14).
We prospectively applied this CCRT with TMZ protocol
to patients with HGG to determine whether it is also
effective for Korean patients with malignant glioma.
Here, we report for the first time the results of CCRT
with TMZ in the treatment of newly diagnosed HGG in
Korea. We compare these results with previously published
results. This is a preliminary report of a prospective study.
MATERIALS AND METHODS
Patients
From June 2004 to August 2007, patients over the age of
17 years with newly diagnosed and histologically confirmed
HGG (World Health Organization [WHO] grade III or
IV) were the subjects of this study. We included in the
study not only glioblastoma but also WHO grade III glioma,
which is well known to have an unfavorable prognosis.
The patients were required to have a Karnofsky perfor-
mance status (KPS)≥70 and adequate hematological,
renal, and hepatic functions, defined as an absolute neu-
trophil count≥1500/μL, platelet count≥100,000/μL,
hemoglobin≥10 g/dL, serum creatinine and total serum
bilirubin less than 1.5 times the upper limit of normal,
aspartate aminotransferase and alanine aminotransferase
less than 2.5 times the upper limit of normal, and alkaline
phosphatase less than twice the upper limit of normal.
Patients were not eligible if they were in poor medical
condition, which could interfere with the oral admin-
istration of TMZ. All patients were required to give their
written informed consent.
Treatment
The patients eligible for study inclusion were treated with
concomitant cranial RTx and CTx with TMZ, using the
protocol proposed by Stupp et al. in 200213). According to
this protocol, the RTx component of the CCRT consisted
of fractionated focal irradiation at a dose of 2 Gy per fraction
given once a day, five days a week for a period of six weeks,
a total dose of 60 Gy. The TMZ component of the CCRT
was given at a dose of 75 mg/m2 per day for seven days per
week from the first day of RTx until the last day of RTx but
for no longer than 49 days. TMZ was administered daily 1
hour before RTx, or in the morning on days without RTx.
After a four-week break, the patients then received up to six
cycles of adjuvant TMZ, according to the standard five-day
schedule, every 28 days. The dose was 150 mg/m2 for the
first cycle and was increased to 200 mg/m2 at the beginning
of the second cycle if there were no hematological toxic
effects. Prophylaxis for Pneumocystis carinii pneumonia
was recommended during CCRT, or if lymphocyte counts
decreased below 500/mm3.
Patient assessments
Baseline evaluations including patient history, physical
examination, performance scale, hematology, and clinical
chemistry assessments, and magnetic resonance (MR) images
of the brain with gadolinium enhancement were performed
before surgery. MR scans were performed before the first
adjuvant treatment cycle and then every two or three months
during the first year and every three months during the
second year. The patients were categorized into four groups :
complete response (complete disappearance of the targeted
lesion), partial response (over 25% volume reduction of the
targeted lesion), stable disease (less than 25% volume change
in the targeted lesion), and progressive disease (over 25%
volume increase in the targeted lesion), taking the initial
baseline measurements as a reference.
Toxic effects were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(version 3.0), with a score of 1 indicating mild adverse effects;
a score of 2, moderate adverse effects; a score of 3, severe
adverse effects; and a score of 4, life-threatening adverse
effects.
Statistical analysis
Progression-free survival (PFS) was calculated from the
date of diagnosis, when the pathology was confirmed, to
the date of brain MR imaging that showed progression of
the disease. Overall survival (OS) was calculated from the
date of diagnosis until death or the date of the last follow-
up. Both sets of data were analyzed with the Kaplan-Meier
method using the SPSS statistical software package (release
12.0, 2004; SPSS Inc., Chicago, IL).




Thirty-two patients who were eligible for the study were
enrolled. Their median age was 53.5 years (range, 17-74).
The characteristics of the patients are summarized in Table
1. A histological review confirmed the diagnosis of glioblas-
toma in 18 patients (>50%), eight patients had anaplastic
astrocytoma (WHO grade III), and four patients were diag-
nosed with anaplastic oligodendroglioma (WHO grade III).
The median time from diagnosis to the start of therapy
was 3.1 weeks (range, 1.2-6.0). Table 2 summarizes the
details of treatment. Seven patients showed complete
remission, and 11 patients displayed partial remission.
However, disease progression was observed in five patients.
Survival and progression
At the time of this analysis, 13 patients died, and three
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Table 2. Disposition of Patients and Intensity of Treatment
Variable
Radiotherapy plus temozolomide 












Duration of CCRT (weeks)
Median 7
Range 3.1-8.0
















Data missing 4 (13)
Response
Complete remission 7 (22)
Partial remission 11 (34)
Stable disease 5 (16)
Progressive disease 5 (16)
Data missing 4 (13)
Table 1. Demographic characteristics of 32 patients at baseline
Characteristic
Radiotherapy plus temozolomide 
No. of patient (%)
Age (years)
Median                                                  53.5
Range                                                    17-74
<50 yr 13 (41)






















Time from diagnosis to 
radiotherapy (weeks)
Median 3.1









Data missing 9 (28)
Findings on pathological review 
Glioblastoma 18 (56)
Anaplastic astrocytoma 8 (25)
Anaplastic oligodendroglioma 4 (13)
Gliomatosis cerebri 2 (6)
KPS : Karnofsky performance status, CCRT : concomitant chemoradiotherapy, 
GTR : gross total removal, NTR : near-total removal, STR : subtotal removal, PR :
partial removal, STBx : stereotactic biopsy. 
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patients had been lost to follow-up after dropping out of
the study. The CCRT was stopped for four patients in the
middle of the course, because of their poor general condition.
Adjuvant chemotherapy with TMZ was continued for an
average of 5.6 cycles (range, 1-15) in 26 patients. Five patients
showed progressive disease during adjuvant chemotherapy.
There was no mortality caused by drug toxicity. The mean
duration of follow-up was 12.5 months (range, 3-48).
Based on the Kaplan-Meier method, the median PFS of
these patients was 9.0 months (95% confidence interval,
5.8-12.2), and the six-month PFS rate was 72.4%. The
median OS was 26 months (95% confidence interval, 8.3-
43.7), and the one-year and two-year OS rates were 83.6%
and 34.4%, respectively. The OS and PFS are summarized
at Table 3. The response rate, including complete remission
and partial remission, was 56%. Kaplan-Meier survival
curves for HGG are illustrated in Fig. 1.
The 18 patients with glioblastoma were analyzed separately
from the other patients with HGG, and the median OS
was 18 months (95% confidence interval, 13.0-23.0), and
the one-year and two-year OS rates were 81.8% and 40.9%,
respectively. The median PFS was seven months (95%
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Fig. 2. Kaplan-Meier estimates of progression-free survival (PFS) (A) and OS (B) in 18 patients with glioblastoma (WHO grade IV) treated with
concomitant chemoradiotherapy  with temozolomide. The median PFS is seven months (95% CI, 5.4-8.6), and the six-month PFS rate is 75.0%. The
median OS is 18 months (95% CI, 13.0-23.0), and the one-year and two-year OS rates are 81.8% and 40.9%, respectively.
A B









PFS (months) (n=29) 9.0
Range* 5.8-12.2
Six-month PFS  72.4%
*range : 95% confidence interval. OS : overall survival, PFS : progression free
survival
Fig. 1. Kaplan-Meier estimates of progression-free survival (PFS) (A) and overall survival (OS) (B) in patients suffering from primary high-grade
glioma (WHO grade III and IV) treated with concomitant chemorad-iotherapywith temozolomide. The median PFS of these patients is 9.0 months
(95% Confidential Index, 5.8-12.2), and the six-month PFS rate is 72.4%. The median OS was 26 months (95% CI, 8.3-43.7), and the one-year and
two-year OS rates are 83.6% and 34.4%, respectively.
A B
confidence interval, 5.4-8.6), and the six-month PFS rate
was 75.0%. Kaplan-Meier survival curves for glioblastoma
only are illustrated in Fig. 2.
The prognosis by surgical respectability was also analyzed
in these 28 patients. Gross total removal (GTR), near total
removal (NTR) and subtotal removal (STR) were achieved
in 15 patients, and partial removal (PR) or stereotactic biopsy
were conducted in 13 patients. The mean OS of GTR,
NTR and STR groups was 34.2 months, and the mean OS
of STR and biopsy groups was 20.9 months. One-year and
two-year OS rates of the former groups were 81.8% and
51.9%, respectively. One-year and two-year OS rates of the
other groups were 84.6% and 52.9%. There was no
significant difference in the aspect of OS rates between two
groups. The median PFS of the GTR, NTR and STR
groups was 10 months (95% confidence interval, 4.7-15.3),
and the six-month PFS rate was 62.5%. On the other
hands, the median PFS of the PR and biopsy groups was 6
months (95% confidence interval, 2.0-10.0), and the six-
month PFS rate was 53.8%.
Toxicity
During CCRT, thrombocytopenia was detected in seven
patients (22%). Grades 1 and 2 thrombocytopenia were
documented in one patient and six patients, respectively.
Two patients developed leukocytopenia, and one patient
developed anemia. Overall, 10 patients (21%) had some type
of hematological toxic effect. Nonhematological toxicities
were mild. Nausea and vomiting were reported in 10 patients
(21%), of whom eight had a grade 1 toxic effect and two
had a grade 2 effect, but they were controlled well with
antiemetics given before the chemotherapeutic medication.
Mild muscle weakness was observed in one patient.
DISCUSSION
TMZ is a novel, second-generation, oral alkylating agent
that has demonstrated antitumor activity in the treatment
of malignant gliomas. TMZ has been approved for the
treatment of recurrent malignant glioma but has also has
shown activity in patients with newly diagnosed malignant
glioma1,5,13,18).
In 2002, a promising regimen of CCRT with adjuvant
TMZ CTx for patients with glioblastoma was reported13).
With reference to this pilot study, we proceeded to apply
CCRT, using the same protocol, to patients with HGG from
2004. Unlike the previous report, we extended the applica-
tion of CCRT to treat WHO grade III gliomas, including
anaplastic astrocytoma and anaplastic oligodendroglioma,
as well as glioblastoma.
While our prospective study was in progress, some other
reports of CCRT with TMZ for HGG were published. In
2005, the efficacy of postoperative TMZ radiochemotherapy
in malignant glioma was reported in Germany7). According
to that report, median PFS times were 7.3 and 8.7 months
for primary glioblastoma and anaplastic astrocytoma, respec-
tively, in patients treated with CCRT with TMZ. That
study also reported that the median survival time for patients
with glioblastoma was 14.6 months and the two-year survi-
val rate for anaplastic astrocytoma was 33%. Our prelimi-
nary results for CCRT in patients with HGG are as good
as those published outcomes.
As previously mentioned, a randomized prospective study
of concomitant TMZ combined with RTx was reported in
2005 to be more effective than RTx alone in patients with
newly diagnosed glioblastoma15). This randomized study
compared RTx plus concomitant TMZ with RTx alone in
patients with newly diagnosed, histologically confirmed
glioblastoma. It reported that the median survival for pati-
ents with glioblastoma was 14.6 months with RTx plus
TMZ and 12.1 months with RTx alone. The two-year
survival rate was 26.5% with RTx plus TMZ and 10.4%
with RTx alone. That study confirmed the effectiveness of
CCRT with TMZ for glioblastoma patients. At present
CCRT followed by a single-agent adjuvant treatment with
the alkylating agent TMZ is widely accepted as the current
standard care for patients with glioblastoma9,10,14). Our
results for the 18 patients with glioblastoma in our series are
similar to the results of recent reports. Therefore, CCRT
with TMZ can also be used as the standard protocol for the
treatment of WHO grade IV glioma in Korea.
Unlike glioblastoma, there is no definite consensus about
the standard regimen for WHO grade III gliomas, such as
anaplastic astrocytoma and anaplastic oligodendroglioma.
For example, a phase III trial of CTx plus RTx using procar-
bazine, lomustine, and vincristine (PCV) to treat anaplastic
oligodendroglioma was published in 20063). This study
concluded that PCV plus RTx did not prolong the survival
of patients with anaplastic oligodendroglioma and the
longer PFS was associated with significant toxicity. There-
fore, it is essential to verify the role of TMZ in the treatment
of WHO grade III glioma. Since the above-mentioned
landmark study of Stupp et al. in 2005, there have been
many phase II and III clinical studies of the treatment of
HGG with TMZ in adults4,9). These trials have reported
good outcomes, and our present results for patients with
WHO grade III and IV gliomas are also favorable, with
tolerable toxicity. In our study, the median PFS and OS of
patients with HGG treated with CCRT were nine months
and 26 months, respectively. Our results are consistent with
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those of many other reports, confirming that CCRT with
TMZ adjuvant CTx offers good clinical outcomes in the
treatment of HGG. Therefore, we propose CCRT with
TMZ as an alternative approach for patients with WHO
grade III gliomas, as well as for those with glioblastoma.
The analysis of MGMT and the loss of heterozygosity at
chromosomes 1p/19q were not separately investigated in
this study, but research into these is ongoing. The correlation
with these factors will be described in our final report. An
interrelationship between racial differences and treatment
results may also exist, and studies of this will be necessary in
the future.
CONCLUSION
This is the first report of results of CCRT with TMZ in
the treatment of HGG in Korea. This Korean trial of
CCRT and adjuvant chemotherapy with TMZ in HGG
patients demonstrated survival outcomes consistent with
those of other previous trials, with tolerable toxicities.
Therefore, we suggest that CCRT with TMZ should be
considered as a standard therapy in Korea for patients with
HGG. To confirm this, a multicenter, meta-analysis and a
randomized trial with a large number of patients are required
in the near future.
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